Medtronic faces patent review revival as Fed Cir faults PTAB

Precedential decision marks blow for medical device maker after earlier win | PTAB criticised for “fundamental legal error” and “narrow definition”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’

10 February 2026 Telehealth platform faces legal action from the Danish pharma giant, as well as FDA pressure over GLP-1 drugs and a drop in shares after discontinuing new product.

Americas

Novartis takes aim at Tafinlar generic in latest suit

9 February 2026 The Swiss pharma giant moves to protect patents on its billion-dollar cancer therapy following an ANDA filing by a Canadian generics manufacturer.

Americas

Semaglutide patent battle heats up with new blow for Novo in India

6 February 2026 A Delhi High Court ruling signals more bad news for the Danish pharma giant in the same week that it lost nearly $50 billion in value.

More features

Hogan Lovells makes senior public and administrative hire in Italy

Danaher moves to acquire Masimo in $9.9bn deal

Generic rival blocked as AZ defends diabetes stronghold

Emotional Perception exclusive: ‘We are now very much open for business’

New rankings recognise top US patent firms and lawyers

Norton Rose Fulbright expands pharma and biotech disputes team

UPC appeals court confirms ‘all-or-nothing’ rule for unitary patents

Honigman bags second Kirkland litigator this year for IP team

Medtronic faces patent review revival as Fed Cir faults PTAB

More on this story

Editor's picks

Editor's picks

More features